Market Intelligence, Preclinical Progress, and High-Purity Reagents for Transmembrane Protein Target Validation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMEM86A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM86A Extracellular Domain / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View TMEM86A Products |
| Gene Delivery | TMEM86A Promise-ORF / Lentivirus. Full-length ORF for stable cell lines (Optimal for complex membrane targets). | View TMEM86A Products |
| Benchmark Ab | Anti-TMEM86A (Reference Clone). Recombinant positive control. | View TMEM86A Products |
| Validator | TMEM86A siRNA Set. For knockdown verification. | View TMEM86A Products |
| Related Target A | TMEM86B. Homolog counter-screening target for specificity validation. | View TMEM86B Products |
| Related Target B | TMEM16A. Synergistic transmembrane target often overexpressed in epithelial tumors. | View TMEM16A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex membrane topology (Multi-pass protein) | Lentivirus Premade Particles for stable cell line generation. HEK293 Expressed (Native Glycosylation). |
| Subfamily counter screening (TMEM86B) | Homolog panel proteins strictly verified by mass spec and Sequence Verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
| Cross-species preclinical safety evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. |
| Subcellular localization & binding epitope mapping | Anti-TMEM86A benchmark antibody (Sequence Verified) for ICC/Flow. |
Live TMEM86A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
TMEM86A (Transmembrane Protein 86A) is an emerging multi-pass membrane target positioned at the intersection of lysosomal and lipid homeostasis. Currently lacking disclosed Phase I clinical programs, the immediate competitive focus shifts toward rigorous target validation and assay standardization. Academic literature suggests roles in autophagic flux and intracellular cholesterol trafficking, creating a strategic window for first-in-class modalities. As an emerging complex multi-pass membrane protein, TMEM86A is gaining traction in oncology research, with major players exploring novel pan-cancer transcriptomic biomarkers. As first-generation target validation progresses, the next wave of R&D is targeting ADC development utilizing highly specific extracellular loop binders, requiring stringent conformational assays.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Early-stage Biotechs, Academic Consortia | Solid Tumors, Refractory Carcinomas | Internalization Assay (Need Lentivirus-driven stable cell lines for native conformation) |
| Monoclonal Antibody (mAb) / Probe Programs | Discovery-stage R&D, Undisclosed | Tumor Microenvironment Modulation, Metabolic disease | Selectivity Assay vs TMEM86B; Native conformation binding (Need full-length Lentivirus cell lines) |
| siRNA / Gene Therapy | Preclinical Discovery | Metabolic / Oncologic Dysfunction | Knockdown Validation (Need Sequence Verified Gene Delivery tools and ORF rescue) |
| Small Molecule Modulators | Academic consortia | Dyslipidemia | Selectivity vs TMEM paralogs (Need homolog panel proteins) |
Molecular Differentiation & Assay Strategies
As a multi-pass transmembrane protein, successful drug development for TMEM86A critically depends on precise molecular design and physiologically relevant in vitro screening systems.
- Affinity & Epitope: Extracellular loops (ECLs) are short and conformational. High-affinity antibodies recognizing native conformational epitopes are essential. Cell-based flow cytometry (FACS) is the gold standard; avoid conventional ELISA.
- Internalization for ADC: Receptor-mediated internalization rate determines payload release efficiency. Use pH-sensitive fluorescent probes or live-cell confocal imaging.
- Safety & Off-target: Must distinguish from paralogs like TMEM86B to avoid cross-reactivity. Cross-reactivity panel screening with homolog proteins is necessary.
- Cross-species Translationality: Evaluate sequence conservation across human, cynomolgus monkey, and mouse. Use ortholog proteins for preclinical toxicity assessment.
TarMart's solution centers on full-length lentivirus stable cell lines to preserve native membrane topology, coupled with validated siRNA for specificity control and benchmark antibodies for subcellular localization. All recombinant proteins are sequence-verified with endotoxin <1 EU/μg.